However, that assay is limited in that not all patients with monoclonal gammopathy show abnormal free light chain measurements. Within the last year, a novel assay which can identify and quantitate ...

Lonza’s bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct heterodimerization of light and heavy chains during bispecific production can be challenging, ...

In contrast to mutation-based engineering, ALiCE harnesses innate assembly mechanisms in cell lines, elegantly utilizing the innate affinity of the heavy chain–light chain variable domains (VH ...

The method for creating bispecific κλ bodies is simple: a production cell expresses a single heavy chain, alongside κ and λ light chains, which self-assemble into functional antibodies.